Tazemetostat
CAS No. : 1403254-99-8
(Synonyms: EPZ-6438; E-7438)
| Size | Price | Stock |
|---|---|---|
| 1mg | $30 | In-stock |
| 5mg | $60 | In-stock |
| 10mg | $84 | In-stock |
| 50mg | $120 | In-stock |
| 100mg | $190 | In-stock |
| 200mg | $290 | In-stock |
| 500mg | $600 | In-stock |
| 1g | $960 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-13803 |
| M.Wt: | 572.74 |
| Formula: | C34H44N4O4 |
| Purity: | >98 % |
| Solubility: | 0.1 M HCL : 14.29 mg/mL (ultrasonic;adjust pH to 5 with HCl);DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 60°C) |
Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells[1]. IC50 & Target:Ki: 2.5 nM (EZH2)[1] In Vitro:Tazemetostat (EPZ-6438) inhibits multi wild-type and mutant lymphoma cell lines proliferation with IC50s of 0.49 nM-7.6 μM[1]. In Vivo:Tazemetostat (EPZ-6438; 250 or 500 mg/kg twice daily for 21-28 days) practically eliminates the fast-growing G401 tumors[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Tazemetostat
- Cat. No.:
- HY-13803
- Quantity:
Your information is safe with us.